Publications by authors named "D Jullien"

201 Publications

Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study.

J Eur Acad Dermatol Venereol 2021 Jun 17. Epub 2021 Jun 17.

Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK.

Indirect excess morbidity in the COVID-19 pandemic may arise from public health risk-mitigation efforts such as stay-at-home orders and re-purposing of healthcare services . Increased mental health disorders and shortfalls in the care of long-term conditions are described.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.17450DOI Listing
June 2021

Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2.

J Eur Acad Dermatol Venereol 2021 Jun 16. Epub 2021 Jun 16.

Dermatology Department, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.17451DOI Listing
June 2021

Characteristics of patients with PASI <10 psoriasis treated with biological agents: Results from the French PsoBioTeq cohort.

Br J Dermatol 2021 Jun 15. Epub 2021 Jun 15.

INSERM, Pierre Louis Institute for Epidemiology and Public Health, Assistance Publique - Hôpitaux de Paris (AP-HP). Sorbonne University, Pitié Salpêtrière Hospitals, Public Health Department, Pharmacoepidemiology Centre, CIC-1422, Paris, France.

Decision to initiate systemic therapy in psoriasis is mainly based on disease severity assessments, determined using physicians' derived scores, e.g. the Psoriasis Area and Severity Index (PASI), an absolute value of 10 or more indicates severe disease. How patients perceive the severity of psoriasis and physicians' evaluation may be discordant, especially when lesions involve visible areas, or are associated with itching, therefore having a greater impact on quality of life (QoL) as evaluated using patient-reported outcomes, like the Dermatology Life Quality Index (DLQI).
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.20585DOI Listing
June 2021

Practical management of patients on anti-IL17 therapy - the CRI guidelines.

Joint Bone Spine 2021 May;88(3S1):105209

Service de Rhumatologie, CHU Sainte-Marguerite, Marseille, France.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2021.105209DOI Listing
May 2021
-->